Literature DB >> 29346042

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Hedy L Kindler1, Nofisat Ismaila1, Samuel G Armato1, Raphael Bueno1, Mary Hesdorffer1, Thierry Jahan1, Clyde Michael Jones1, Markku Miettinen1, Harvey Pass1, Andreas Rimner1, Valerie Rusch1, Daniel Sterman1, Anish Thomas1, Raffit Hassan1.   

Abstract

Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 222 relevant studies to inform the evidence base for this guideline. Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma. Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .

Entities:  

Mesh:

Year:  2018        PMID: 29346042      PMCID: PMC8058628          DOI: 10.1200/JCO.2017.76.6394

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  266 in total

1.  Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.

Authors:  Maurizio Infante; Emanuela Morenghi; Edoardo Bottoni; Paolo Zucali; Daoud Rahal; Andrea Morlacchi; Anna Maria Ascolese; Fiorenza De Rose; Pierina Navarria; Alessandro Crepaldi; Alberto Testori; Emanuele Voulaz; Valentina Errico; Matteo Perrino; Marta Scorsetti; Arturo Chiti; Armando Santoro; Marco Alloisio
Journal:  Eur J Cardiothorac Surg       Date:  2016-06-21       Impact factor: 4.191

2.  How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?

Authors:  Annabel J Sharkey; Kenneth J O'Byrne; Apostolos Nakas; Sara Tenconi; Dean A Fennell; David A Waller
Journal:  Lung Cancer       Date:  2016-07-22       Impact factor: 5.705

3.  Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.

Authors:  William W Chance; David C Rice; Pamela K Allen; Anne S Tsao; Hiral P Fontanilla; Zhongxing Liao; Joe Y Chang; Chad Tang; Hubert Y Pan; James W Welsh; Reza J Mehran; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-25       Impact factor: 7.038

4.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Authors:  Robert Ryan Meyerhoff; Chi-Fu Jeffrey Yang; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

5.  Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series.

Authors:  Hubert Y Pan; Shengpeng Jiang; Jordan Sutton; Zhongxing Liao; William W Chance; Steven J Frank; X Ronald Zhu; Heng Li; Hiral P Fontanilla; Xiaodong Zhang; Daniel R Gomez
Journal:  Pract Radiat Oncol       Date:  2015-01-06

6.  Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy.

Authors:  John M Alvarez; Arman Hasani; Amanda Segal; Greg Sterret; Michael Millward; Ana Nowak; William Musk; Sean Bydder
Journal:  ANZ J Surg       Date:  2009-10       Impact factor: 1.872

7.  Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.

Authors:  C Boutin; F Rey
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

8.  Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.

Authors:  Bogdan D Grigoriu; Bachar Chahine; Anil Vachani; Thomas Gey; Massimo Conti; Daniel H Sterman; Genevieve Marchandise; Henri Porte; Steven M Albelda; Arnaud Scherpereel
Journal:  Am J Respir Crit Care Med       Date:  2009-02-06       Impact factor: 21.405

9.  Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma.

Authors:  Jérôme Krayenbuehl; Peter Dimmerling; I Frank Ciernik; Oliver Riesterer
Journal:  Radiat Oncol       Date:  2014-01-24       Impact factor: 3.481

10.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Authors:  Martin F Muers; Richard J Stephens; Patricia Fisher; Liz Darlison; Christopher M B Higgs; Erica Lowry; Andrew G Nicholson; Mary O'Brien; Michael Peake; Robin Rudd; Michael Snee; Jeremy Steele; David J Girling; Matthew Nankivell; Cheryl Pugh; Mahesh K B Parmar
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

View more
  89 in total

1.  Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial.

Authors:  Pyng Lee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Extended pleurectomy decortication: the current role.

Authors:  Rocco Bilancia; Marco Nardini; David A Waller
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 3.  Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.

Authors:  Charlotte De Bondt; Ioannis Psallidas; Paul E Y Van Schil; Jan P van Meerbeeck
Journal:  Transl Lung Cancer Res       Date:  2018-10

4.  The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity?

Authors:  David A Waller
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

5.  Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment.

Authors:  Malgorzata Szolkowska; Katarzyna Blasinska-Przerwa; Magdalena Knetki-Wroblewska; Piotr Rudzinski; Renata Langfort
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 6.  Is there a role for immunotherapy in malignant pleural mesothelioma?

Authors:  Alfredo Tartarone; Rosa Lerose; Michele Aieta
Journal:  Med Oncol       Date:  2018-05-29       Impact factor: 3.064

Review 7.  Use of Immune Checkpoint Inhibitors in Mesothelioma.

Authors:  Patrick M Forde; Arnaud Scherpereel; Anne S Tsao
Journal:  Curr Treat Options Oncol       Date:  2019-02-14

8.  International trends in the clinical epidemiology of malignant pleural mesothelioma.

Authors:  Ronald A M Damhuis; Jan P van Meerbeeck
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 9.  Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.

Authors:  Lisa Brusselmans; Lieselot Arnouts; Charissa Millevert; Joyce Vandersnickt; Jan P van Meerbeeck; Kevin Lamote
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 10.  Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

Authors:  Paul Halford; Amelia O Clive
Journal:  Transl Lung Cancer Res       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.